S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IF... by C. Touzeau, A. Perrrot, C. Hulin, S. Manier, M. Macro, M.-L. Chretien, L. Karlin, O. Decaux, C. Jacquet, M. Tiab, X. Leleu, L. Planchce, H. Avet-Loiseau, P. Moreau

Get full text

Expressed fusion gene landscape and its impact in multiple myeloma by A. Cleynen, R. Szalat, M. Kemal Samur, S. Robiou du Pont, L. Buisson, E. Boyle, M. L. Chretien, K. Anderson, S. Minvielle, P. Moreau, M. Attal, G. Parmigiani, J. Corre, N. Munshi, H. Avet-Loiseau

Get full text

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE by A. Schavgoulidze, A. Perrot, T. Cazaubiel, X. Leleu, S. Manier, L. Buisson, S. Maheo, L. Do Souto Ferreira, R. Lannes, L. Pavageau, C. Hulin, J.-P. Marolleau, L. Voillat, K. Belhadj, M. Divoux, B. Slama, S. Brechignac, M. Macro, A.-M. Stoppa, L. Sanhes, F. Orsini-Piocelle, J. Fontan, M.-L. Chretien, H. Demarquette, M. Mohty, H. Avet-Loiseau, J. Corre

Get full text